Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review

References

• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi: 10.1016/j.cmet.2015.12.006
   PubMed Web of Science ®Google Scholar
• Houtkooper RH, Cantó C, Wanders RJ, et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010 Apr;31(2):194–223. doi: 10.1210/er.2009-0026
   PubMed Web of Science ®Google Scholar
• Dölle C, Skoge RH, Vanlinden MR, et al. NAD biosynthesis in humans–enzymes, metabolites and therapeutic aspects. Curr Top Med Chem. 2013;13(23):2907–2917. doi: 10.2174/15680266113136660206
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Orsomando G, Sorci L, et al. Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues. Biochim Biophys Acta. 2015;1854(9):1138–1149. doi: 10.1016/j.bbapap.2015.02.021
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Dölle C, Felici R, et al. The NAD metabolome — a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741–752. doi: 10.1038/nrc3340
   PubMed Web of Science ®Google Scholar
• Audrito V, Messana VG, Brandimarte L, et al. The extracellular NADome modulates immune responses. Front Immunol. 2021;12:704779. doi: 10.3389/fimmu.2021.704779
   PubMed Web of Science ®Google Scholar
• Zamporlini F, Ruggieri S, Mazzola F, et al. Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD + biosynthetic machinery in mammalian cells. FEBS J. 2014;281(22):5104–5119. doi: 10.1111/febs.13050
   PubMed Web of Science ®Google Scholar
• Garten A, Schuster S, Penke M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535–546. doi: 10.1038/nrendo.2015.117
   PubMed Web of Science ®Google Scholar
• Heske CM. Beyond energy metabolism: exploiting the additional roles of NAMPT for Cancer Therapy. Front Oncol. 2020;9:1514. doi: 10.3389/fonc.2019.01514
   PubMed Web of Science ®Google Scholar
• Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: two metabolic enzymes with key roles in inflammation. Front Oncol. 2020;10:358. doi: 10.3389/fonc.2020.00358
   PubMed Web of Science ®Google Scholar
• Audrito V, Managò A, Gaudino F, et al. Targeting metabolic reprogramming in metastatic melanoma: the key role of nicotinamide phosphoribosyltransferase (NAMPT). Semin Cell Dev Biol. 2020;98:192–201. doi: 10.1016/j.semcdb.2019.05.001
   PubMed Web of Science ®Google Scholar
• Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor 1. FEBS Lett. 2003;544(1–3):74–78. doi: 10.1016/S0014-5793(03)00476-9
   PubMed Web of Science ®Google Scholar
• Pittelli M, Formentini L, Faraco G, et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem. 2010;285(44):34106–34114. doi: 10.1074/jbc.M110.136739
   PubMed Web of Science ®Google Scholar
• Svoboda P, Krizova E, Sestakova S, et al. Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle–dependent in mammalian cells, and its inhibition slows cell growth. J Biol Chem. 2019;294(22):8676–8689. doi: 10.1074/jbc.RA118.003505
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu J, Park J, et al. Subcellular compartmentalization of NAD+ and its role in cancer: a sereNade of metabolic melodies. Pharmacol Ther. 2019;200:27–41. doi: 10.1016/j.pharmthera.2019.04.002
   PubMed Web of Science ®Google Scholar
• Takahashi R, Nakamura S, Nakazawa T, et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem. 2010;147(1):95–107. doi: 10.1093/jb/mvp152
   PubMed Web of Science ®Google Scholar
• Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006;13(7):582–588. doi: 10.1038/nsmb1105
   PubMed Web of Science ®Google Scholar
• Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD Biosynthetic Enzyme. Cell Metab. 2007;6(5):363–375. doi: 10.1016/j.cmet.2007.09.003
   PubMed Web of Science ®Google Scholar
• van den Bergh R, Morin S, Sass HJ, et al. Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT. PLoS One. 2012;7(4):e35074. doi: 10.1371/journal.pone.0035074
   PubMed Web of Science ®Google Scholar
• Torretta S, Colombo G, Travelli C, et al. The cytokine nicotinamide phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5). Cells. 2020;9(2):496. doi: 10.3390/cells9020496
   PubMed Web of Science ®Google Scholar
• Ratnayake D, Nguyen PD, Rossello FJ, et al. Macrophages provide a transient muscle stem cell niche via NAMPT secretion. Nature. 2021;591(7849):281–287. doi: 10.1038/s41586-021-03199-7
   PubMed Web of Science ®Google Scholar
• Camp SM, Ceco E, Evenoski CL, et al. Unique toll-like receptor 4 activation by NAMPT/PBEF induces NFκB signaling and inflammatory lung injury. Sci Rep. 2015;5(1):13135. doi: 10.1038/srep13135
   PubMedGoogle Scholar
• Carbone F, Liberale L, Bonaventura A, et al. Regulation and function of extracellular nicotinamide phosphoribosyltransferase/Visfatin. Compr Physiol. 2017;7:603–621.
   PubMed Web of Science ®Google Scholar
• Managò A, Audrito V, Mazzola F, et al. Extracellular nicotinate phosphoribosyltransferase binds toll like receptor 4 and mediates inflammation. Nat Commun. 2019;10(1):4116. doi: 10.1038/s41467-019-12055-2
   PubMedGoogle Scholar
• Romacho T, Valencia I, Ramos-González M, et al. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for toll-like receptor 4 and NLRP3 inflammasome. Sci Rep. 2020;10(1):5386. doi: 10.1038/s41598-020-62190-w
   PubMed Web of Science ®Google Scholar
• Gasparrini M, Mazzola F, Cuccioloni M, et al. Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and toll-like receptor 4. J Biol Chem. 2022;298(3):101669. doi: 10.1016/j.jbc.2022.101669
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? [published correction appears in Trends Biochem Sci. 2016 Mar;41(3): 287] [published correction appears in Trends Biochem Sci. 2016 Mar;41(3): 287]. Trends Biochem Sci. 2016;41(3):211–218. doi: 10.1016/j.tibs.2015.12.001
   PubMed Web of Science ®Google Scholar
• Chowdhry S, Zanca C, Rajkumar U, et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature. 2019;569:570–575. doi: 10.1038/s41586-019-1150-2.
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metabolism. 2018;82:72–87. doi: 10.1016/j.metabol.2018.01.001
   PubMed Web of Science ®Google Scholar
• Yaku K, Okabe K, Hikosaka K, et al. NAD metabolism in cancer therapeutics. Front Oncol. 2018;8:622. doi: 10.3389/fonc.2018.00622
   PubMed Web of Science ®Google Scholar
• Tan B, Dong S, Shepard RL, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ biosynthesis, leads to altered carbohydrate metabolism in cancer cells. J Biol Chem. 2015;290(25):15812–15824. doi: 10.1074/jbc.M114.632141
   PubMed Web of Science ®Google Scholar
• Audrito V, Managò A, La Vecchia S, et al. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. J Natl Cancer Inst. 2018;110(3):290–303. doi: 10.1093/jnci/djx198
   Google Scholar
• Kennedy BE, Sharif T, Martell E, et al. NAD+ salvage pathway in cancer metabolism and therapy. Pharmacol Res. 2016;114:274–283. doi: 10.1016/j.phrs.2016.10.027
   PubMed Web of Science ®Google Scholar
• Yong J, Cai S, Zeng Z. Targeting NAD+ metabolism: dual roles in cancer treatment. Front Immunol. 2023;14:1269896. doi: 10.3389/fimmu.2023.1269896
   PubMedGoogle Scholar
• Audrito V, Managò A, Gaudino F, et al. NAD-Biosynthetic and consuming enzymes as central players of metabolic regulation of innate and adaptive Immune Responses in Cancer. Front Immunol. 2019;10:1720. doi: 10.3389/fimmu.2019.01720
   PubMed Web of Science ®Google Scholar
• Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, et al. NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP. Clin Cancer Res. 2018;24(5):1202–1215. doi: 10.1158/1078-0432.CCR-17-2575
   PubMed Web of Science ®Google Scholar
• Silveira SC, Buhagiar-Labarchède G, Onclercq-Delic R, et al. A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD. Sci Rep. 2020;10(1):13907. doi: 10.1038/s41598-020-70874-6
   PubMed Web of Science ®Google Scholar
• Zhao E, Hou J, Ke X, et al. The roles of sirtuin family proteins in cancer progression. Cancers (Basel). 2019;11(12):1949. doi: 10.3390/cancers11121949
   PubMed Web of Science ®Google Scholar
• Zhang B, Shi D, Zhang X, et al. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells. Oncol Lett. 2018;16:7231–7238. doi: 10.3892/ol.2018.9541
   PubMed Web of Science ®Google Scholar
• Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells. Biochim Biophys Acta. 2008;1783(5):886–895. doi: 10.1016/j.bbamcr.2008.01.004
   PubMed Web of Science ®Google Scholar
• Soncini D, Caffa I, Zoppoli G, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 2014;289(49):34189–34204. doi: 10.1074/jbc.M114.594721
   PubMed Web of Science ®Google Scholar
• Kim JY, Bae YH, Bae MK, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta. 2009;1793(11):1759–1767. doi: 10.1016/j.bbamcr.2009.09.006
   PubMed Web of Science ®Google Scholar
• Sica A, Strauss L, Consonni FM, et al. Metabolic regulation of suppressive myeloid cells in cancer. Cytokine Growth Factor Rev. 2017;35:27–35. doi: 10.1016/j.cytogfr.2017.05.002
   PubMed Web of Science ®Google Scholar
• Dutta T, Kapoor N, Mathew M, et al. Source of nicotinamide governs its metabolic fate in cultured cells, mice, and humans. Cell Rep. 2023;42(3):112218. doi: 10.1016/j.celrep.2023.112218
   PubMed Web of Science ®Google Scholar
• Murphy JP, Giacomantonio MA, Paulo JA, et al. The NAD+ salvage pathway supports PHGDH-Driven serine biosynthesis. Cell Rep. 2018;24(9):2381–2391.e5. doi: 10.1016/j.celrep.2018.07.086
   PubMed Web of Science ®Google Scholar
• Touat M, Sourisseau T, Dorvault N, et al. DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. J Clin Invest. 2018;128(4):1671–1687. doi: 10.1172/JCI90277
   PubMed Web of Science ®Google Scholar
• Wang W, Yang C, Wang T, et al. Complex roles of nicotinamide N-methyltransferase in cancer progression. Cell Death Dis. 2022;13(3):267. doi: 10.1038/s41419-022-04713-z
   PubMed Web of Science ®Google Scholar
• Ghanem MS, Monacelli F, Nencioni A. Advances in NAD-Lowering agents for cancer treatment. Nutrients. 2021;13(5):1665. doi: 10.3390/nu13051665
   PubMed Web of Science ®Google Scholar
• Cea M, Cagnetta A, Fulciniti M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012;120(17):3519–3529. doi: 10.1182/blood-2012-03-416776
   PubMed Web of Science ®Google Scholar
• Kozako T, Aikawa A, Ohsugi T, et al. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor. Eur J Pharmacol. 2019;865:172738. doi: 10.1016/j.ejphar.2019.172738
   PubMed Web of Science ®Google Scholar
• Gasparrini M, Audrito V. NAMPT: A critical driver and therapeutic target for cancer. Int J Biochem Cell Biol. 2022;145:106189. doi: 10.1016/j.biocel.2022.106189
   PubMed Web of Science ®Google Scholar
• Quijada H, Bermudez T, Kempf CL, et al. Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody. Eur Respir J. 2021;57(5):2002536. doi: 10.1183/13993003.02536-2020
   PubMed Web of Science ®Google Scholar
• Colombo G, Clemente N, Zito A, et al. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. J Mol Med (Berl). 2020;98(4):595–612. doi: 10.1007/s00109-020-01892-0
   PubMed Web of Science ®Google Scholar
• Garcia AN, Casanova NG, Kempf CL, et al. eNAMPT is a novel damage-associated molecular pattern protein that contributes to the severity of radiation-induced lung fibrosis. Am J Respir Cell Mol Biol. 2022;66(5):497–509. doi: 10.1165/rcmb.2021-0357OC
   PubMed Web of Science ®Google Scholar
• Forma Tm, Llc. Novel compounds and compositions for the inhibition of nampt. WO2012150952A1. 2012.
   Google Scholar
• Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt. WO2012031199A1. 2012.
   Google Scholar
• Forma Therapeutics, Inc. Genentech, Inc. 4- {[(pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer. WO2012031196A1. 2012.
   Google Scholar
• Genentech Inc, Forma Therapeutics Inc, Valo Early Discovery Inc. Novel compounds and compositions for the inhibition of nampt. US20210244717A1. 2021.
   Google Scholar
• Valo Health Inc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt). US20230110003A1. 2023.
   Google Scholar
• Abbott Laboratories. Nampt inhibitors. WO2012067963A1. 2012.
   Google Scholar
• Abbvie Inc. Nampt inhibitors. US20160193209A1. 2016.
   Google Scholar
• AbbVie Inc. Nampt inhibitors. US20170253562A1. 2017.
   Google Scholar
• Abbott Laboratories. Nampt and rock inhibitors. US20120122842A1. 2012.
   Google Scholar
• AbbVie Inc. Nampt inhibitors. US20130303508A1. 2013.
   Google Scholar
• Abbvie Inc. Nampt inhibitors. WO2013170113A1. 2013.
   Google Scholar
• AbbVie Inc. Nampt inhibitors. US20170065575A1. 2017.
   Google Scholar
• Aurigene Discovery Technologies Limited. 4,5-dihydroisoxazole derivatives as nampt inhibitors. WO2014111871A1. 2014.
   Google Scholar
• Aurigene Discovery Technologies Limited. 4,5-dihydroisoxazole derivatives as nampt inhibitors. WO2016012958A1. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. Fused heterocyclyl derivatives as nampt inhibitors. WO2014141035A3. 2015.
   Google Scholar
• Zhang RY, Qin Y, Lv XQ, et al. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. Anal Biochem. 2011;412(1):18–25. doi: 10.1016/j.ab.2010.12.035
   PubMed Web of Science ®Google Scholar
• The Curators of The University of Missouri. Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt).WO2013082150A1. 2013.
   Google Scholar
• Genzyme Corporation. Nampt inhibitors and methods. WO2015179759A1. 2015.
   Google Scholar
• Eli Lilly And Company. Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors. WO2015054060A1. 2015.
   Google Scholar
• Sunflower Research Llc. Therapeutic and diagnostic methods. US20160367541A1. 2016.
   Google Scholar
• Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors. WO2018075600A1. 2018.
   Google Scholar
• University Of Pittsburgh. Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity. WO2022109285A1. 2022.
   Google Scholar
• Arizona Board of Regents of University of Arizona. Compositions and methods for treating pulmonary fibrosis. US20200138799A1. 2020.
   Google Scholar
• University Of California. Interferon signaling as a cancer biomarker. WO2021102420A1. 2021.
   Google Scholar
• New York University NYU. Combination therapy for treatment of lkb1 deficient cancers. US20220062260A1. 2022.
   Google Scholar
• Zhang Y, Meng Q, Sun Q, et al. LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases. Mol Metab. 2021;44:101131. doi: 10.1016/j.molmet.2020.101131
   PubMed Web of Science ®Google Scholar
• Bayer Pharma Aktiengesellschaft. Dihydropyridazinones substituted with phenylureas. WO2018086703A1. 2018.
   Google Scholar
• Bayer Aktiengesellschaft. Bayer Pharma Aktiengesellschaft. Antibody drug conjugates (adcs) with nampt inhibitors. WO2019149637A1. 2019.
   Google Scholar
• Ontario Institute For Cancer Research (Oicr). Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof. 2022:p. WO2022011458A1.
   Google Scholar
• Ontario Institute For Cancer Research (Oicr). Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof. 2022:p. US20220313832A1.
   Google Scholar
• Università Degli Studi Del Piemonte Orientale “Amedeo Avogadro”. “inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof”. 2014:p. WO2014178001A1.
   Google Scholar
• Università Degli Studi Di Genova. Centre Hospitalier Universitaire Vaudois (Chuv). Sensitization of cancer cells to nampt inhibitors by nicotinic acid phosphoribosyltransferase neutralization. 2017:p. WO2017162840A1.
   Google Scholar
• Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof. WO2015161142A1. 2015.
   Google Scholar
• Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof. WO2016118565A1. 2016.
   Google Scholar
• Mor Research Applications Ltd. Methods for prognosis and treatment of solid tumors. US20210180138A1. 2021.
   Google Scholar
• Institut National de la Sante et de la Recherche Medicale INSERM, Universite Cote dAzur. Methods and compositions for treating melanoma resistant. 2021:p. US20210072244A1.
   Google Scholar
• Apion Japan KK. Novel nampt inhibitor and an antitumor agent containing the same, screening method for novel nampt inhibitor, novel naprt inhibitor and antitumor agent containing the same, screening method for novel naprt inhibitor, method for increasing ratio of normal cells to tumor cells, and method to assist in prescribing antitumor agents. JP2019137638A. 2019.
   Google Scholar
• Opko Curna Llc. Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt. 2012:p. WO2012024478A2.
   Google Scholar
• Tian Lizhi. A kind of sulfamide derivative, preparation method and its it is antitumor in application. CN107903246A. 2018.
   Google Scholar
• Tian Lizhi. A kind of sulfamide derivative, preparation method and its application as NAMPT inhibitor in antitumor drug. CN107954988A. 2018.
   Google Scholar
• Tian Lizhi. A kind of sulfamide derivative and its application in antitumor drug. CN107954987A. 2018.
   Google Scholar
• Tian Lizhi. A kind of sulfamide derivative and its application as NAMPT inhibitor. CN108042538A. 2018.
   Google Scholar
• Second Military Medical University SMMU. A kind of Nampt nitrogen mustards inhibitor of multiple target point anti-tumor activity and its preparation and application. CN109776494A. 2019.
   Google Scholar
• Second Military Medical University SMMU. NAMPT protein degradation targeting chimera and preparation method and application thereof. CN111454327A. 2020.
   Google Scholar
• Second Military Medical University SMMU. Compound and application thereof in preparation of NAMPT protein autophagy degradation agent. CN114890990A. 2022.
   Google Scholar
• Juyuan Shanghai Biotechnology Co ltd. NAMPT/HDAC double-target inhibitor and preparation method thereof. CN106916101A. 2017.
   Google Scholar
• China Pharmaceutical University. A kind of novel NAMPT and IDO double inhibitors and preparation method thereof and medical usage. CN108530444A. 2018.
   Google Scholar
• China Pharmaceutical University. A kind of benzo-aza virtue cyclics and its preparation method and application. CN107674059A. 2018.
   Google Scholar
• Tianjin University of Science and Technology. Novel method for inhibiting activity of colon cancer cells by combining inhibitor and small interfering RNA. CN112156105A. 2021.
   Google Scholar
• East China Normal University. Nicotinamide phosphoribosyl transferase inhibitors with tumor targeting. CN113896721A. 2022.
   Google Scholar
• East China University of Science and Technology, Second Military Medical University SMMU. Compound serving as NAMPT-PDE delta double-target inhibitor and application thereof. CN116589402A. 2023.
   Google Scholar
• Gasparrini M, Sorci L, Raffaelli N. Enzymology of extracellular NAD metabolism. Cell Mol Life Sci. 2021;78(7):3317–3331. doi: 10.1007/s00018-020-03742-1
   PubMed Web of Science ®Google Scholar
• Galli U, Colombo G, Travelli C, et al. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy. Front Pharmacol. 2020;11:656. doi: 10.3389/fphar.2020.00656
   PubMed Web of Science ®Google Scholar
• Semerena E, Nencioni A, Masternak K. Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker. Front Immunol. 2023;14:1268756. doi: 10.3389/fimmu.2023.1268756
   PubMed Web of Science ®Google Scholar
• Piacente F, Caffa I, Ravera S, et al. Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT Inhibitors, and DNA repair. Cancer Res. 2017;77(14):3857–3869. doi: 10.1158/0008-5472.CAN-16-3079
   PubMed Web of Science ®Google Scholar
• Antolin AA, Workman P, Mestres J, et al. Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Curr Pharm Des. 2016;22(46):6935–6945. doi: 10.2174/1381612822666160923115828
   PubMed Web of Science ®Google Scholar
• Amelio I, Lisitsa A, Knight RA, et al. Polypharmacology of approved anticancer drugs. Curr Drug Targets. 2017;18(5):534–543. doi: 10.2174/1389450117666160301095233
   PubMed Web of Science ®Google Scholar
• Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200. doi: 10.1038/s41573-021-00371-6
   PubMed Web of Science ®Google Scholar
• Wu Y, Pu C, Fu Y, et al. NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion. Acta Pharm Sin B. 2022;12(6):2859–2868. doi: 10.1016/j.apsb.2021.12.017
   PubMed Web of Science ®Google Scholar
• Zhu X, Liu H, Chen L, et al. Addressing the enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation. Cell Chem Biol. 2022;29(11):1616–1629.e12. doi: 10.1016/j.chembiol.2022.10.007
   PubMed Web of Science ®Google Scholar